Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective Study
Luciano Ibba, Sara Di Giulio, Piergiorgio Malagoli, Anna Balato, Federico Bardazzi, Massimo Travaglini, Giampiero Girolomoni, Martina Maurelli, Martina Burlando, Stefano Caccavale, Carlo G. Carrera, Andrea Carugno, Paolo Dapavo, Eugenia V. Di Brizzi, Valentina Dini, Francesca M. Gaiani, Claudio Guar · 2026
Read Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective Study by Luciano Ibba, Sara Di Giulio, Piergiorgio Malagoli, Anna Balato, Federico Bardazzi, Massimo Travaglini, Giampiero Girolomoni, Martina Maurelli, Martina Burlando, Stefano Caccavale, Carlo G. Carrera, Andrea Carugno, Paolo Dapavo, Eugenia V. Di Brizzi, Valentina Dini, Francesca M. Gaiani, Claudio Guar (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13493664.txt.
Description
Ibba and a large Italian team report a 2026 real-world study of secukinumab, a biologic drug for psoriasis, tracked for up to seven years. Records came from 15 dermatology units covering 769 adults with moderate-to-severe disease who stayed on treatment at least four years. Effectiveness was judged with the PASI score, which grades how much skin is affected and how badly, and the team also logged every reported side effect.
Response deepened steadily over time, with about nine in ten remaining patients reaching at least 90 percent skin improvement by year six. Complete skin clearance also became more common as the years passed, and results held up in patients with other health problems or hard-to-treat body areas. People who also had psoriatic arthritis cleared fully at especially high rates in years five and six. No new safety concerns appeared over the long follow-up.
Catalog record
| CREATOR | Luciano Ibba, Sara Di Giulio, Piergiorgio Malagoli, Anna Balato, Federico Bardazzi, Massimo Travaglini, Giampiero Girolomoni, Martina Maurelli, Martina Burlando, Stefano Caccavale, Carlo G. Carrera, Andrea Carugno, Paolo Dapavo, Eugenia V. Di Brizzi, Valentina Dini, Francesca M. Gaiani, Claudio Guar |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |